More recently, the abundance and spatial distribution of CD86+ antigen-presenting B cells have been described in tumor samples of cancer patients, indicating that they are elevated in TILs, localized in TLS, and enriched in tumors with increased TLSs (68). This evidence concerns the gene CD86 and cancer.